{"id":"sabin-ipv","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site pain, redness, or swelling"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Irritability or fussiness"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Sabin IPV contains chemically inactivated (killed) poliovirus particles of serotypes 1, 2, and 3. When administered, these antigens trigger both humoral (antibody) and cellular immune responses without causing disease. The resulting antibodies neutralize wild-type poliovirus and prevent viral replication in the gastrointestinal and nervous systems, thereby preventing paralytic poliomyelitis.","oneSentence":"Sabin IPV is an inactivated polio vaccine that stimulates the immune system to produce antibodies against all three poliovirus serotypes, preventing poliomyelitis infection.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:06:32.687Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of poliomyelitis caused by poliovirus serotypes 1, 2, and 3"}]},"trialDetails":[{"nctId":"NCT07457060","phase":"PHASE4","title":"Phase IV Clinical Study of Sequential Vaccination of Sabin Strain and Wild Strain Inactivated Poliovirus Vaccine","status":"RECRUITING","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2025-11-27","conditions":"Poliomyelitis","enrollment":480},{"nctId":"NCT07354269","phase":"PHASE4","title":"Phase IV Clinical Study of sIPV Administration in Adolescent and Adult Populations","status":"RECRUITING","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2025-09-26","conditions":"Poliomyelitis","enrollment":180},{"nctId":"NCT07338851","phase":"","title":"the Five-year Antibody Persistence After Immunization With IPV, MMR and HepA-L Vaccines","status":"NOT_YET_RECRUITING","sponsor":"China National Biotec Group Company Limited","startDate":"2026-01-30","conditions":"Polio, Measles, Rubella","enrollment":600},{"nctId":"NCT05644184","phase":"PHASE2","title":"Study of a Novel Type 1 Oral Poliomyelitis Vaccine in Bangladesh","status":"RECRUITING","sponsor":"PATH","startDate":"2023-03-27","conditions":"Poliomyelitis","enrollment":2232},{"nctId":"NCT07297186","phase":"PHASE3","title":"Phase III Clinical Trial of Sabin Strain Inactivated Poliovirus Vaccine (Vero Cell)","status":"COMPLETED","sponsor":"Beijing Minhai Biotechnology Co., Ltd","startDate":"2017-08-21","conditions":"Poliomyelitis","enrollment":1200},{"nctId":"NCT05850364","phase":"PHASE3","title":"A Multi-center, Open-labelled, Randomized, Controlled, Extended Phase Ⅲ Clinical Trial of sIPV Vaccine","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2023-05-22","conditions":"Poliomyelitis, Polio","enrollment":1442},{"nctId":"NCT06331156","phase":"PHASE3","title":"A Study on the Immune Response and Safety of Inactivated Poliovirus Vaccine (IPV) When Co-administered With Human Rotavirus (HRV) Porcine Circovirus (PCV)-Free Vaccine in Healthy Chinese Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2024-03-22","conditions":"Gastroenteritis","enrollment":400},{"nctId":"NCT06920069","phase":"PHASE4","title":"Study of Concomitant Administration of the sIPV and DTaP or MMR","status":"NOT_YET_RECRUITING","sponsor":"Institute of Medical Biology, Chinese Academy of Medical Sciences","startDate":"2025-05-15","conditions":"Polio, Diphteria, Tetanus and Pertussis, MMR Vaccine","enrollment":2640},{"nctId":"NCT05431933","phase":"PHASE3","title":"Study to Evaluate Eupolio(IPV)'s Safety, Long-term Protective Effect and Boosting Effect of One Booster Dose in the Three Primary Vaccination Plus Boosting Schedule, and Protective Effect in the Schedule With Bivalent OPV in Infants","status":"COMPLETED","sponsor":"LG Chem","startDate":"2023-01-10","conditions":"Poliomyelitis, Vaccine Reaction","enrollment":2001},{"nctId":"NCT05460377","phase":"PHASE4","title":"Assessing Immunogenicity of Intramuscular Sabin Inactivated Poliovirus Vaccine and Non-inferiority of Intradermal Fractional Inactivated Poliovirus Vaccine","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2022-07-26","conditions":"Poliomyelitis","enrollment":1224},{"nctId":"NCT03566940","phase":"PHASE2","title":"A Study to Assess the Safety, Reactogenicity and Immunogenicity of a Trivalent Inactivated Poliovirus Vaccine (IPV) Based on Sabin Strains Compared to Conventional Salk IPV in a 6, 10 and 14 Weeks of Age Immunization Schedule","status":"COMPLETED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2018-07-31","conditions":"Healthy","enrollment":302},{"nctId":"NCT03032588","phase":"PHASE1","title":"A First in Human Study to Assess the Safety, Tolerability and Immunogenicity of a Single Dose of a Trivalent Inactivated Poliovirus Vaccine Based on Sabin Strains (sIPV) Given Intramuscularly in Healthy Adults","status":"COMPLETED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2017-10-09","conditions":"Healthy","enrollment":32},{"nctId":"NCT03848065","phase":"PHASE1","title":"Safety, Tolerability, and Immunogenicity of V114 in Healthy Japanese Infants (V114-028)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-04-02","conditions":"Pneumococcal Infections","enrollment":133},{"nctId":"NCT06752174","phase":"PHASE3","title":"A Study to Evaluate Safety and Immunogenicity of Sequential Vaccination of Sabin Inactivated Poliomyelitis Vaccine (Vero Cell) and Live Attenuated Poliomyelitis Vaccine in Healthy 2-month-old Infants","status":"COMPLETED","sponsor":"Beijing Minhai Biotechnology Co., Ltd","startDate":"2023-03-08","conditions":"Poliomyelitis","enrollment":300},{"nctId":"NCT04529538","phase":"PHASE1","title":"Study of Novel Types 1 and 3 Oral Poliomyelitis Vaccines","status":"COMPLETED","sponsor":"PATH","startDate":"2021-03-26","conditions":"Poliomyelitis","enrollment":226},{"nctId":"NCT02961595","phase":"PHASE1","title":"Live Enterovirus Vaccine and Type 1 Diabetes","status":"COMPLETED","sponsor":"Tampere University","startDate":"1999-10","conditions":"Enterovirus Infection, Type 1 Diabetes, Prediabetic State","enrollment":315},{"nctId":"NCT04481191","phase":"PHASE3","title":"Immunogenicity and Safety of Concomitant and Non-Concomitant Administration of RotaTeq® (V260) and Inactivated Poliomyelitis Vaccine in Healthy Chinese Infants (V260-074)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-08-25","conditions":"Prevention of Rotavirus Gastroenteritis in Infants and Children Caused by Serotypes G1, G2, G3, G4, and G9","enrollment":400},{"nctId":"NCT06460545","phase":"PHASE4","title":"Phase IV Study of Concomitant Administration of the sIPV and HepA","status":"NOT_YET_RECRUITING","sponsor":"Institute of Medical Biology, Chinese Academy of Medical Sciences","startDate":"2024-06-15","conditions":"Polio, Hepatitis A","enrollment":2000},{"nctId":"NCT05386810","phase":"PHASE3","title":"Safety of Sabin Inactivated Poliovirus Vaccine in Adults, Children and Infants and Lot Consistency Immunogenicity, and Safety of the msIPV in 2 Months Old Infants","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2020-11-05","conditions":"Poliomyelitis","enrollment":1572},{"nctId":"NCT05654467","phase":"PHASE2","title":"Study of a Novel Type 3 Oral Poliomyelitis Vaccine in Panama","status":"UNKNOWN","sponsor":"PATH","startDate":"2023-12-05","conditions":"Poliomyelitis","enrollment":1532},{"nctId":"NCT05327426","phase":"PHASE1","title":"Intradermal Fractional Dose IPV (fIPV) in Combination With dmLT","status":"UNKNOWN","sponsor":"University of Vermont","startDate":"2022-04-01","conditions":"Poliomyelitis","enrollment":19},{"nctId":"NCT06058429","phase":"","title":"Immunogenicity of After Primary Immunization and Booster Immunization of sIPV","status":"UNKNOWN","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2023-08-16","conditions":"Polio","enrollment":233},{"nctId":"NCT03614702","phase":"PHASE3","title":"Clinic Trial to Evaluate the Safety and Immunogenicity by Different Sequential Schedules of bOPV and IPV","status":"COMPLETED","sponsor":"Institute of Medical Biology, Chinese Academy of Medical Sciences","startDate":"2015-09-15","conditions":"Poliomyelitis","enrollment":1200},{"nctId":"NCT04220515","phase":"PHASE4","title":"Inactivated Poliomyelitis Vaccine Made From Sabin Strain","status":"COMPLETED","sponsor":"Institute of Medical Biology, Chinese Academy of Medical Sciences","startDate":"2018-02-08","conditions":"Poliomyelitis","enrollment":49731},{"nctId":"NCT01510366","phase":"PHASE3","title":"The Clinical Trial Protocol for the Inactivated Poliomyelitis Vaccine Made From Sabin Strains(Sabin IPV)","status":"COMPLETED","sponsor":"Institute of Medical Biology, Chinese Academy of Medical Sciences","startDate":"2012-01","conditions":"Poliomyelitis","enrollment":1200},{"nctId":"NCT04224519","phase":"PHASE4","title":"Consistency Study for Three Commercial Lots of Inactivated Poliomyelitis Vaccine Made From Sabin Strain","status":"COMPLETED","sponsor":"Institute of Medical Biology, Chinese Academy of Medical Sciences","startDate":"2018-04-15","conditions":"Poliomyelitis","enrollment":1200},{"nctId":"NCT05952596","phase":"PHASE1","title":"A Study to Evaluate Safety and Immunogenicity of APV006 in Healthy Adults","status":"UNKNOWN","sponsor":"LG Chem","startDate":"2023-07-17","conditions":"Diphtheria, Tetanus, Pertussis","enrollment":42},{"nctId":"NCT05457946","phase":"PHASE2, PHASE3","title":"Study to Evaluate the Immunogenicity and Safety of LBVD(Hexavalent Vaccine), Given to Healthy Infants at Primary Series","status":"UNKNOWN","sponsor":"LG Chem","startDate":"2023-04-01","conditions":"Diphtheria, Tetanus, Pertussis","enrollment":1438},{"nctId":"NCT05432141","phase":"PHASE4","title":"A Safety Study of Sabin Inactivated Poliovirus Vaccine in Infants","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2022-06-13","conditions":"Poliomyelitis","enrollment":3200},{"nctId":"NCT04989231","phase":"","title":"An Immunity Persistence Study of Sabin Inactivated Poliovirus Vaccine(Vero Cell) After Four Doses","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2021-09-09","conditions":"Poliomyelitis","enrollment":450},{"nctId":"NCT04232943","phase":"PHASE1","title":"Inactivated Poliovirus Vaccine (IPV) With or Without E.Coli Double Mutant Heat-Labile Toxin (dmLT) Challenge Study in Healthy Adults","status":"COMPLETED","sponsor":"PATH","startDate":"2020-01-22","conditions":"Polio","enrollment":87},{"nctId":"NCT04054882","phase":"PHASE4","title":"Evaluation of the Safety and Immunogenicity of Simultaneously Administration of sIPV and DTaP","status":"COMPLETED","sponsor":"China National Biotec Group Company Limited","startDate":"2019-08-16","conditions":"Vaccination","enrollment":702},{"nctId":"NCT04614597","phase":"","title":"A Study on Immunity Duration Against Polio Over 18 Months Infants After 2 or 3 Primary Doses Sabin IPV in China","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention, China","startDate":"2020-10-29","conditions":"Poliomyelitis","enrollment":774},{"nctId":"NCT04576910","phase":"PHASE4","title":"Immunogenicity and Safety of the Booster Dose of Polio Vaccine With Different Primary Sequential Schedules in China","status":"COMPLETED","sponsor":"Zhejiang Provincial Center for Disease Control and Prevention","startDate":"2020-11-05","conditions":"Polio, Vaccine Reaction","enrollment":387},{"nctId":"NCT04544787","phase":"PHASE2","title":"A Phase 2 Study to Evaluate the Safety and Immunogenicity of Two Oral Poliovirus Vaccine Candidates","status":"COMPLETED","sponsor":"Pierre Van Damme","startDate":"2018-10-22","conditions":"Poliomyelitis","enrollment":250},{"nctId":"NCT04386707","phase":"PHASE3","title":"Lot-consistency Clinical Trial of Sabin Strain Inactivated Polio Vaccine","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2020-05-11","conditions":"Poliomyelitis","enrollment":1300},{"nctId":"NCT03430349","phase":"PHASE1","title":"Phase 1 Novel Live Attenuated Serotype 2 Oral Polio Vaccine Study in Inactivated Polio Vaccine (IPV) Primed Adults","status":"COMPLETED","sponsor":"Pierre Van Damme","startDate":"2017-05-16","conditions":"Poliomyelitis","enrollment":30},{"nctId":"NCT04638985","phase":"PHASE4","title":"Evaluation of Immunogenicity and Safety of Combined Immunization of sIPV, DTaP and MMR","status":"UNKNOWN","sponsor":"China National Biotec Group Company Limited","startDate":"2020-11-13","conditions":"Vaccine","enrollment":600},{"nctId":"NCT04636827","phase":"PHASE4","title":"Evaluation of Safety and Immunogenicity of Combined Immunization of sIPV, DTaP and HepA","status":"UNKNOWN","sponsor":"China National Biotec Group Company Limited","startDate":"2020-11-11","conditions":"Vaccination","enrollment":600},{"nctId":"NCT04618783","phase":"NA","title":"Cross-neutralization Capacity of Immune Serum From Different Dosage of Sabin Inactivated Poliovirus Vaccine Immunization","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2019-07-20","conditions":"Poliomyelitis","enrollment":250},{"nctId":"NCT04051736","phase":"PHASE4","title":"Immunogenicity and Safety of Sabin-IPV Replacement Vaccination","status":"COMPLETED","sponsor":"China National Biotec Group Company Limited","startDate":"2018-03-01","conditions":"Vaccination","enrollment":360},{"nctId":"NCT02521974","phase":"PHASE4","title":"A Study to Evaluate the Safety and Immunogenicity of Oral Polio Vaccine Type 2 in Infants and Children","status":"COMPLETED","sponsor":"Fidec Corporation","startDate":"2015-10","conditions":"Adverse Event Following Immunisation","enrollment":164},{"nctId":"NCT03546634","phase":"PHASE4","title":"Sero-conversion Study for a Two-dose Schedule of Sabin IPV in China","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention, China","startDate":"2018-05-24","conditions":"Poliomyelitis","enrollment":280},{"nctId":"NCT03597919","phase":"PHASE4","title":"A Study of Immunogenicity and Seroconversion With Sabin IPV Schedules in China.","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention, China","startDate":"2018-05-28","conditions":"Poliomyelitis","enrollment":560},{"nctId":"NCT04264546","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity of a Sabin Inactivated Poliovirus Vaccine (Phase Ib)","status":"COMPLETED","sponsor":"Jiangsu Province Centers for Disease Control and Prevention","startDate":"2017-11-24","conditions":"Polio","enrollment":60},{"nctId":"NCT04264598","phase":"PHASE1","title":"Safety and Immunogenicity of a Sabin Inactivated Poliovirus Vaccine","status":"COMPLETED","sponsor":"Jiangsu Province Centers for Disease Control and Prevention","startDate":"2017-08-21","conditions":"Polio","enrollment":100},{"nctId":"NCT03092791","phase":"PHASE1, PHASE2","title":"IPV-102 Safety, Tolerability and Immunogenicity of TAK-195 in Healthy Infants, Toddlers and Adults","status":"TERMINATED","sponsor":"Takeda","startDate":"2017-06-07","conditions":"Poliomyelitis","enrollment":340},{"nctId":"NCT02582255","phase":"PHASE4","title":"A Study to Evaluate the Safety and Immunogenicity of Monovalent OPV2 in Children Aged 1 to 5 Years in Lithuania","status":"COMPLETED","sponsor":"Fidec Corporation","startDate":"2015-11","conditions":"Poliomyelitis","enrollment":100},{"nctId":"NCT03147560","phase":"PHASE4","title":"Immunogenicity and Safety Evaluation of Different Sequential Immunization Strategies by Sabin IPV and bOPV in Chinese Infants","status":"COMPLETED","sponsor":"Zhejiang Provincial Center for Disease Control and Prevention","startDate":"2017-05-02","conditions":"Polio","enrollment":528},{"nctId":"NCT04073459","phase":"PHASE2","title":"Safety and Immunogenicity of Hexavalent Vaccine(DTwP-HepB-IPV-Hib) in Healthy Infants","status":"UNKNOWN","sponsor":"LG Chem","startDate":"2019-11","conditions":"Diphtheria, Tetanus, Pertussis","enrollment":336},{"nctId":"NCT03169725","phase":"PHASE2, PHASE3","title":"A Clinical Study to Evaluate the Safety and Immunogenicity of Inactivated Poliomyelitis Vaccine in Healthy Infants","status":"COMPLETED","sponsor":"LG Chem","startDate":"2017-05-31","conditions":"Poliomyelitis","enrollment":1417},{"nctId":"NCT04054492","phase":"PHASE4","title":"To Evaluate the Immunogenicity and Safety of Sequential Immunization Schedules of Sabin IPV and bOPV","status":"COMPLETED","sponsor":"China National Biotec Group Company Limited","startDate":"2018-03-01","conditions":"Vaccination, Reaction - Vaccine","enrollment":604},{"nctId":"NCT04053010","phase":"PHASE4","title":"Clinic Trial to Evaluate the Safety and Immunogenicity of Combined Immunization of sIPV and DTaP","status":"UNKNOWN","sponsor":"China National Biotec Group Company Limited","startDate":"2019-08-10","conditions":"Vaccination","enrollment":702},{"nctId":"NCT03902054","phase":"PHASE2","title":"Safety and Immunogenicity of a Sabin Inactivated Poliovirus Vaccine.","status":"COMPLETED","sponsor":"Jiangsu Province Centers for Disease Control and Prevention","startDate":"2017-12-28","conditions":"Polio and Post-Polio Syndrome","enrollment":600},{"nctId":"NCT03822767","phase":"PHASE3","title":"A Clinical Trial to Evaluate the Immunogenicity and Safety of sIPV in a \"2+1\"Sequential Schedule With bOPV in Infants","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2018-06-12","conditions":"Poliomyelitis","enrollment":240},{"nctId":"NCT03822754","phase":"PHASE3","title":"A Clinical Trial to Evaluate the Immunogenicity and Safety of sIPV in a '1+2' Sequential Schedule With bOPV in Infants","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2018-06-06","conditions":"Poliomyelitis","enrollment":240},{"nctId":"NCT03526978","phase":"PHASE3","title":"An Immunogenicity and Safety Study of Sabin Inactivated Poliovirus Vaccine (Vero Cell) in 2-month-old Infants","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2017-08-08","conditions":"Poliomyelitis","enrollment":1200},{"nctId":"NCT00547248","phase":"PHASE3","title":"Pneumococcal Vaccine Booster Study in Healthy Children 12-18 Mths Old Previously Primed With the Same Vaccines","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-10-22","conditions":"Infections, Streptococcal","enrollment":756},{"nctId":"NCT00344318","phase":"PHASE3","title":"Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' 10-valent Pneumococcal Conjugate Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-08-07","conditions":"Infections, Streptococcal","enrollment":806},{"nctId":"NCT02985320","phase":"PHASE1, PHASE2","title":"Studies of the Safety and Immunogenicity of a Sabin Inactivated Poliovirus Vaccine","status":"COMPLETED","sponsor":"Sinovac Biotech Co., Ltd","startDate":"2016-10","conditions":"Poliomyelitis","enrollment":708},{"nctId":"NCT02477046","phase":"PHASE3","title":"Assessment of Community Transmission of Sabin Type 2 Virus in Bangladesh","status":"UNKNOWN","sponsor":"University of Virginia","startDate":"2015-04","conditions":"Vaccine Virus Shedding","enrollment":810},{"nctId":"NCT01056705","phase":"PHASE2","title":"The Clinical Trial Protocol for the Inactivated Poliomyelitis Vaccine Made From Sabin Strains (IPV)","status":"COMPLETED","sponsor":"Chinese Academy of Medical Sciences","startDate":"2009-07","conditions":"Poliomyelitis","enrollment":500},{"nctId":"NCT01831050","phase":"PHASE4","title":"Safety and Immunogenicity of 1 or 2 Doses of IPV in Latin American Infants Primed With Bivalent OPV Vaccine","status":"COMPLETED","sponsor":"Fidec Corporation","startDate":"2013-05","conditions":"Poliomyelitis","enrollment":1420},{"nctId":"NCT01708720","phase":"PHASE1","title":"Safety and Immunogenicity of a New Inactivated Polio Vaccine in Healthy Adults","status":"COMPLETED","sponsor":"Pauline Verdijk","startDate":"2011-08","conditions":"Poliomyelitis","enrollment":45},{"nctId":"NCT01709071","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity of a New Inactivated Poliovirus Vaccine in Infants","status":"COMPLETED","sponsor":"Pauline Verdijk","startDate":"2012-02","conditions":"Poliomyelitis","enrollment":140},{"nctId":"NCT01048190","phase":"PHASE1","title":"The Clinical Trial Protocol for the Inactivated Poliomyelitis Vaccine Made From Sabin Strains","status":"COMPLETED","sponsor":"Chinese Academy of Medical Sciences","startDate":"2008-08","conditions":"Poliomyelitis","enrollment":130}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":48,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Sabin strain Inactivated Poliovirus Vaccine"],"phase":"marketed","status":"active","brandName":"Sabin IPV","genericName":"Sabin IPV","companyName":"Centers for Disease Control and Prevention, China","companyId":"centers-for-disease-control-and-prevention-china","modality":"Biologic","firstApprovalDate":"","aiSummary":"Sabin IPV is an inactivated polio vaccine that stimulates the immune system to produce antibodies against all three poliovirus serotypes, preventing poliomyelitis infection. Used for Prevention of poliomyelitis caused by poliovirus serotypes 1, 2, and 3.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}